10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Pregabalin

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Pregabalin

Pregabalin

Class : A

Show all info

Print

Contact us

  1. Lyrica (pregabalin). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-06-19, cited 2019-09-20].

  2. Lyrica (pregabalin). DailyMed [www]. US National Library of Medicine. [updated 2019-08-28, cited 2019-09-20].

  3. Bockbrader HN, Burger P, Knapp L, Corrigan BW. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia. 2011;52:248-57.

  4. Lyrica (pregabalin) - tvåårsuppföljning. Swedish Medical Products Agency [www]. [updated 2006-11-02, cited 2020-04-16].

  5. Bodén R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol. 2014;70(2):197-204.

  6. Gahr M, Freudenmann RW, Hiemke C, Kölle MA, Schönfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69:1335-42.

  7. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Lyrica (pregabalin). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-06-19, cited 2019-09-20].
  2. Lyrica (pregabalin). DailyMed [www]. US National Library of Medicine. [updated 2019-08-28, cited 2019-09-20].
  3. Bockbrader HN, Burger P, Knapp L, Corrigan BW. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia. 2011;52:248-57.
  4. Lyrica (pregabalin) - tvåårsuppföljning. Swedish Medical Products Agency [www]. [updated 2006-11-02, cited 2020-04-16].
  5. Bodén R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol. 2014;70(2):197-204.
  6. Gahr M, Freudenmann RW, Hiemke C, Kölle MA, Schönfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69:1335-42.
  7. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]